Global Spinal Muscular Atrophy Market to Reach $9.85 Billion by 2035

The global spinal muscular atrophy (SMA) market is poised for significant expansion, growing from $5.8 billion in 2025 to $11.4 billion by 2035, at a CAGR of 7.0% during the forecast period. This growth is primarily driven by rising awareness, early diagnosis, and increasing investment in advanced genetic therapies. A key macro driver accelerating the market is the global expansion of rare disease diagnosis and treatment infrastructure. According to the World Health Organisation (WHO), rare diseases collectively affect nearly 300 million people worldwide, with genetic disorders such as SMA representing a significant share. Additionally, data from the U.S. Food and Drug Administration (FDA) indicates that over 50% of new drug approvals in recent years are focused on rare and orphan diseases, reflecting a strong regulatory push.

Browse the full report description of “Spinal Muscular Atrophy (SMA) Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Gene Therapy, Antisense Oligonucleotide Therapy, Small Molecule Therapy), By Route of Administration (Intravenous, Intrathecal, Oral), By Patient Type (Type 1, Type 2, Type 3, Type 4), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/spinal-muscular-atrophy-sma-treatment-market

Furthermore, the growing adoption of newborn screening programs is directly influencing SMA diagnosis rates. Government-backed initiatives across the U.S., Europe, and parts of Asia-Pacific have expanded early screening coverage. Public health data from OECD countries shows that newborn screening programs now cover over 90% of births in developed regions, enabling early detection and increasing demand for SMA treatments. This directly contributes to higher treatment uptake, particularly for advanced therapies such as gene therapy.

Among product types, gene therapy is emerging as the fastest-growing segment due to its potential for one-time curative treatment. Several strategic developments between 2025 and 2026 highlight how manufacturers are strengthening their position in this segment:

• In February 2026, GEMMABio initiated the Phase 1/2 CHARISMA clinical trial for its next-generation gene therapy (GB221), with the first patient successfully dosed, marking progress in advanced delivery methods targeting cerebrospinal fluid.
• In March 2026, Biogen Inc advanced its pipeline by launching multiple Phase 3 trials (STELLAR & SOLAR) for salanersen, a next-generation antisense therapy aimed at improving outcomes across infant and older SMA patient populations.
• In October 2025, the Indian Supreme Court / Natco Pharma allowed the launch of a generic version of risdiplam, improving affordability and access in emerging markets, which is expected to increase treatment penetration.

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) reports that global biopharmaceutical R&D investment exceeded $198 billion annually, with a significant share directed toward advanced therapies such as gene therapy. Additionally, EvaluatePharma highlights that cell and gene therapy markets are expected to grow at double-digit rates globally, reinforcing the segment’s strong outlook within SMA treatment. The convergence of regulatory support, technological innovation, and increasing healthcare expenditure is creating a favorable ecosystem for SMA therapeutics. Expanding insurance coverage and government reimbursement programs are further supporting patient access, particularly in high-income economies.

Market Coverage

• The market number available for – 2025-2035
  • Base year- 2025
  • Forecast period- 2026-2035
  • Segment Covered-
  o By Treatment Type
  o By Route of Administration
  o By Patient Type
  o By Distribution Channel

o Competitive Landscape-Biogen Inc., Novartis AG, Hoffman-La Roche Ltd, Ionis Pharmaceuticals, Cytokinetics

Key Questions Addressed by the Report

• What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Spinal Muscular Atrophy Market Report Segment

• By Treatment Type
• Gene Therapy
• Antisense Oligonucleotide Therapy
• Small Molecule Therapy
• By Route of Administration
• Type 1 SMA
• 2 Type 2 SMA
• 3 Type 3 SMA
• 4 Type 4 SMA
• By Patient Type
• Intravenous (IV)
• 2 Intrathecal (Spinal Injection)
• 3 Oral
• By Distribution Channel
• Hospital Pharmacies
• Speciality Pharmacies
• Retail Pharmacies

Global Spinal Muscular Atrophy Market Report Segment by Region

North America
• United States
• Canada

Europe
• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World
• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/spinal-muscular-atrophy-sma-treatment-market